Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Accenture
Dow
Colorcon
Cerilliant
Cipla
Fuji
Daiichi Sankyo
AstraZeneca

Generated: November 19, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 206910

« Back to Dashboard

NDA 206910 describes JADENU, which is a drug marketed by Novartis Pharms Corp and is included in two NDAs. It is available from one supplier. There are two patents protecting this drug and three Paragraph IV challenges. Additional details are available on the JADENU profile page.

The generic ingredient in JADENU is deferasirox. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the deferasirox profile page.
Summary for 206910
Tradename:JADENU
Applicant:Novartis Pharms Corp
Ingredient:deferasirox
Patents:2
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 206910
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
JADENU deferasirox TABLET;ORAL 206910 NDA Novartis Pharmaceuticals Corporation 0078-0654 0078-0654-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0654-15)
JADENU deferasirox TABLET;ORAL 206910 NDA Novartis Pharmaceuticals Corporation 0078-0655 0078-0655-15 30 TABLET, FILM COATED in 1 BOTTLE (0078-0655-15)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength90MG
Approval Date:Mar 30, 2015TE:RLD:Yes
Regulatory Exclusivity Expiration:Jan 23, 2020
Regulatory Exclusivity Use:TREATMENT OF CHRONIC IRON OVERLOAD IN PATIENTS 10 YRS. & OLDER WITH NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT) SYNDROMES AND WITH A LIVER IRON CONCENTRATION OF AT LEAST 5 MG OF IRON PER GRAM OF LIVER DRY WEIGHT & SERUM FERRITIN GREATER THAN 300 MCG/L.
Patent:➤ Try a Free TrialPatent Expiration:Apr 5, 2019Product Flag?YSubstance Flag?YDelist Request?
Patent:➤ Try a Free TrialPatent Expiration:Nov 21, 2034Product Flag?YSubstance Flag?YDelist Request?

Expired US Patents for NDA 206910

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-001 Mar 30, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-002 Mar 30, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Novartis Pharms Corp JADENU deferasirox TABLET;ORAL 206910-003 Mar 30, 2015 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Fish and Richardson
Mallinckrodt
Covington
Farmers Insurance
Healthtrust
Dow
Chinese Patent Office
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.